We offer assistance to UNMC and UNO faculty, staff and students interested in starting companies with technology licensed from UNeMed. Entrepreneurs: read more…
UNeMed works with entrepreneurs, investors and consultants to form new companies around disclosed technologies. UNeMed nurtures these companies—identifying early investors, grant opportunities and potential leaders—while often taking an equity stake in the business.
Here’s a selection of active startups that got their start from University of Nebraska innovations. Most are still in early-stage product development and fundraising.
Burch Kealey, Ph.D., developed and licensed software to make EDGAR searches more efficient. Dr. Kealey, an accounting associate professor of at the University of Nebraska at Omaha, developed the program as a way to solve frustrations he encountered during a large research project.
Formed around an siRNA delivery system developed in the lab of Joe Vetro, Ph.D. The siRNA delivery system helps protect the siRNA from degradation and can be used to improve systemic administration of siRNA-based therapies. Actorius Pharmaceuticals is currently developing the siRNA delivery technology to treat various forms of cancer including breast cancer.
Originally named Camras Vision, the startup was founded on an intraocular pressure device developed by the late Carl Camras, M.D., a UNMC physician. His daughter, Lucinda, founded the company.
An early product of the Omaha startup scene and the Biomechanics Department at the University of Nebraska Omaha, Avert is building a non-invasive concussion detection system combining biomechanics, artificial intelligence and cloud computing. The result is highly accurate, low-cost device that can reliably determine when a person receives a concussion and when they recover.
Breezmed is a health informatics startup developing a new platform to ease workflow around prior authorizations. Breezmed streamlines the different documents insurance companies often require, making it easier for patients to get their prescriptions.
BromeCare Therapeutics is currently developing bromelain compounds for nutraceutical and pharmaceutical applications such as prevention and treatment of COVID-19.
Carecubes provides portable, modular negative-pressure isolation chambers designed to allow rapid access to patients while protecting front-line workers.
A phishing training platform, Cyber Train uses a phishing victimization prediction model based on structural indicators of trust. The model—built using data from research studies of hundreds of people and more than 20,000 individual trust decisions—examines trainees to pinpoint the effects of different cues on victimization potential. Underlying research shows that the model successfully predicts victimization, and that subsequent training can reduce the likelihood of being victimized in the future.
Formed around a thermosensitive hydrogel formulation that can be used to deliver a variety of therapeutics. Developed by Dong Wang, Ph.D., the thermosensitive hydrogel formulation is a liquid at room temperature and a hydrogel once injected into the body, allowing for better control of drug releas. Ensign Pharmaceutical is initially focusing the development of the hydrogel formulation for the treatment of osteoarthritis.
Exavir is developing an ultra-long acting antiretroviral portfolio that is a multi-class arsenal for HIV treatment and prevention regimens. Their agents are de-risked by existing antiretrovirals already proven to work at target drug exposure levels. Exavir’s next-generation formulations and CRISPR-based technology are aimed eradicating HIV.
We provide medical devices to assure the future of medical decisions” or “Providing providers validated data that changes people’s lives assuring the right decision.
Impower was created on a remarkable innovation developed at the University of Nebraska at Omaha’s world-class Biomechanics facility: The world’s first biomechanics-based self-pacing treadmill. The treadmill relies on a coordinated sensor system and algorithm to detect the user’s center of mass and leg swing velocity to sense the user’s position and adjust speed accordingly.
Precision Syringe is built on a technology invented by ophthalmologist Donny Suh, MD, who wanted more precision and dexterity when administering eye injections on children. The result is the Suh Precision Syringe, an elegant one-handed syringe that allows clinicians to quickly and accurately perform delicate injections with almost shocking ease. The transformative device dramatically improves patient comfort and care.
Late UNMC researcher Sam Sanderson, Ph.D., founded Prommune to develop his innovation, EP-67, a protein formulation that can serve as a platform to activate and enhance the natural immune system for a number of conditions. Prommune is currently focused on using EP-67 to deliver a more effective vaccine for the H1N1 virus in pigs. In the future, Prommune hopes to expand to other conditions and perhaps human use.
Co-founded by former Entrepreneur-In-Residence, Gary Madsen, Ph.D., ProTransit Nanotherapy is based on the work of former UNMC researcher Vinod Labshetwar, Ph.D., who is also a co-founder in the Omaha-based startup. ProTransit is developing a nanoparticle as a delivery vehicle for antioxidant enzymes to the deepest layers of the skin. The final product could be a topical application such as skin cream or sun lotion that better protects the skin against cancer, blemishes and wrinkles. There is also potential for additional applications that include treatment for some spinal cord injuries or certain types of brain damage.
Greg Gordon, M.D., a former interventional radiologist at UNMC and the Veteran’s Administration, is commercializing new tools that help reduce radiation exposure. The devices also reduce the stress and strain often experienced by interventional radiologists, improving their work flow, efficiency, career longevity and quality of life.
RespirAI is a medical device startup in the pulminary, cardiovascular, and long-term care spaces currently collaborating with Jennifer Yentes, PhD at UNO Biomechanics, Stephen Renard, MD at UNMC College of Medicine and their team to commercialize innovative respiratory monitoring devices.
ScanMed was created in the 1990s when UNMC faculty member Randy Jones, Ph.D., commercialized MRI coils he created. ScanMed later escaped the economic downturn by pivoting into a service company that repairs MRI scanning coils. More recently, ScanMed has enjoyed significant growth and now uses its repair service to bankroll some of the most innovative MRI coil designs in the world, including a novel prostate cancer screening coil that could dramatically improve a physician’s ability to make the earliest possible diagnosis.
Formed to develop a novel glucocorticoid prodrug (ZSJ-0228) developed by UNMC researcher, Dong Wang, Ph.D. The novel glucocorticoid prodrug has improved efficacy and reduced toxicity compared to standard glucocorticoid treatments. Shannon Pharmaceuticals is developing ZSJ-0228 for the treatment of systemic lupus erythematosus and various kidney diseases.
Suh Hermsen Glasses is a leading innovator creating vision solutions for special needs and requirements that traditional eyeglass manufacturers can’t or won’t address. Suh Hermsen Glasses sells hundreds of ergonomic surgical loupe head straps monthly to dentists, ophthalmologists, surgeons, and jewelers, etc. Suh Hermsen Glasses is also developing modular glass frames with a pediatric focus.
Nebraska manufacturing startup Vireo Systems was established in Plattsmouth, Neb., about 20 miles south of Omaha. Vireo manufactures popular muscle-building health supplements that were developed at UNMC, Creatine Ethyl Ester and Creatine HCL. Vireo eventually outgrew its first facility, expanding into a larger space in 2012. More than 20 Nebraskans are employed at Vireo, which holds more than 40 manufacturing contracts.
Virtual Incision was born out of a collaboration between UNMC surgeon Dmitry Oleynikov and UNL robotics engineering professor Shane Farritor. Together, the cofounders are developing miniaturized surgical robots that could transform highly invasive major surgeries into minimally invasive procedures. Their surgical platform has also shown potential for remote surgical applications, and has undergone zero-gravity testing with NASA. In 2015 alone, Virtual Incision raised more than $11.2 million, and entered their first human trials in 2016.